# The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

> **NCT06911710** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tianjin Medical University General Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
- AML (Acute Myelogenous Leukemia)
- Myeloma Multiple
- B-ALL
- T-ALL/Lymphoma
- T-lymphocyte Lymphoma

## Interventions

- **DRUG:** CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）

## Key facts

- **NCT ID:** NCT06911710
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-09
- **Primary completion:** 2026-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06911710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06911710, "The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06911710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*